Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 527
Filtrar
1.
Indian J Pathol Microbiol ; 67(1): 189-191, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38358219

RESUMO

The synchronous occurrence of bilateral ovarian tumors and breast malignancy often raise the suspicion of a Krukenberg tumor or a hereditary breast and ovarian cancer syndrome, both of which are uncommon in clinical practice. A 58-years-old postmenopausal woman had a right breast lump and was diagnosed as infiltrating duct carcinoma, no special type, and incidentally detected bilateral adnexal mass with the clinical suspicion of Krukenberg tumor. However, following the radical surgical excision of the right breast and bilateral ovaries, the right breast showed invasive micropapillary carcinoma (IMPC) while the ovaries showed mature cystic teratoma (MCT) with benign Brenner tumor. IMPC of the breast along with bilateral ovarian MCT with benign Brenner tumor is an unusual clinical occurrence in a postmenopausal female and thus worthy of documentation. It should be categorized as a non-hereditary synchronous tumor. The histomorphology augmented by immunohistochemistry and appropriate clinical context is pivotal in rendering a correct diagnosis.


Assuntos
Tumor de Brenner , Carcinoma , Tumor de Krukenberg , Neoplasias Ovarianas , Teratoma , Feminino , Humanos , Pessoa de Meia-Idade , Tumor de Brenner/diagnóstico , Tumor de Brenner/cirurgia , Pós-Menopausa , Neoplasias Ovarianas/diagnóstico , Neoplasias Ovarianas/cirurgia , Neoplasias Ovarianas/patologia , Teratoma/diagnóstico , Teratoma/cirurgia , Teratoma/patologia
3.
Hum Pathol ; 141: 15-21, 2023 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-37673346

RESUMO

Thirteen years ago, we pointed out that ovarian transitional cell carcinomas (TCCs) and conventional high-grade serous carcinomas (HGSCs) had similar genetic alterations and clinical behavior. Consequently, ovarian TCC is now classified as a morphologic variant of HGSC. Defective homologous recombination, resulting from genetic or epigenetic inactivation of DNA damage repair genes, such as BRCA1/2, occurs in approximately 50% of the HGSCs. Although BRCA mutations have been associated with HGSCs with solid, pseudoendometrioid or transitional (SET) features, little is known about the role of non-BRCA homologous recombinationrepair (HRR) genes and the HRR status in these tumors. Using two commercially available assays (Myriad Genetics MyChoice CDx Plus test and SOPHiA Dx Homologous Recombination Deficiency Solution), we study mutations of BRCA1/2 and non-BRCA HRR genes (ATM, BARD1, BRIP1, CDK12, CHEK1/2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L), and the HRR status in 19 HGSCs with SET features and 20 HGSCs with classic morphology. We also studied, as control cases, 5 endometrioid carcinomas, 1 clear cell carcinoma, 2 low-grade serous carcinomas, and 1 malignant Brenner tumor. Seven HGSCs with SET features (7/19; 37%) showed BRCA mutations (4 BRCA1, 2 BRCA2, and 1 BRCA1/2). Mutations in non-BRCA HRR genes were found in ATM (1/15; 7%), BARD1 (1/15; 7%), and BRIP1 (1/19; 5%). Most HGSCs with SET features (17/19; 90%) were considered to be homologous recombination-deficient tumors. Three HGSCs with classic morphology (3/20; 15%) showed BRCA2 mutations. Mutations in non-BRCA HRR genes were found in CDK12 (2/14; 14%), FANCL (1/14; 7%), RAD51B (1/14; 7%), and RAD54L (1/14; 7%). Eleven HGSCs with classical morphology (11/20; 55%) were considered to be homologous recombination deficient. In contrast, all ovarian carcinoma control cases (5 endometrioid carcinomas, 1 clear cell carcinoma, 2 low-grade serous carcinomas, and 1 malignant Brenner tumor) were homologous recombination proficient and did not have BRCA mutations. Our results show that the majority of HGSCs with SET features are homologous recombination-deficient tumors independently of the BRCA status and highlight the importance of the HRR tumor testing, especially in BRCA wild-type tumors. Recognition of transitional cell variant of HGSCs may help to identify patients most likely to benefit from PARP inhibitors.


Assuntos
Tumor de Brenner , Carcinoma Endometrioide , Cistadenocarcinoma Seroso , Neoplasias Ovarianas , Neoplasias Peritoneais , Feminino , Humanos , Proteína BRCA1/genética , Proteína BRCA2/genética , Neoplasias Ovarianas/genética , Neoplasias Ovarianas/patologia , Mutação , Carcinoma Epitelial do Ovário , Recombinação Homóloga , Neoplasias Peritoneais/patologia , Cistadenocarcinoma Seroso/genética , Cistadenocarcinoma Seroso/patologia
4.
Arch Gynecol Obstet ; 308(3): 961-970, 2023 09.
Artigo em Inglês | MEDLINE | ID: mdl-37186266

RESUMO

PURPOSE: To describe the clinical and sonographic features of ovarian benign Brenner tumor (BBT) and malignant Brenner tumor (MBT), and to compare performance of four diagnostic models in differentiating them. METHODS: Fifteen patients with BBTs and nine patients with MBTs were retrospectively identified in our institution from January 2003 and December 2021. One ultrasound examiner categorized each mass according to ovarian-adnexal reporting and data system (O-RADS), international ovarian tumor analysis (IOTA) Simple Rules Risk (SR-Risk) assessment and assessment of different neoplasias in the adnexa (ADNEX) models with/without CA125. Receiver operating characteristic curves were generated to compare diagnostic performance. RESULTS: Patients with MBT had higher CA125 serum level (62.5% vs. 6.7%, P = 0.009) and larger maximum diameter of lesion (89 mm vs. 43 mm, P = 0.009) than did those with BBT. BBT tended to have higher prevalence of calcifications (100% vs. 55.6%, P = 0.012) and acoustic shadowing (93.3% vs. 33.3%, P = 0.004), and lower color scores manifesting none or minimal flow (100.0% vs. 22.2%, P < 0.001). Areas under curves of O-RADS, IOTA SR-Risk and ADNEX models with/without CA125 were 0.896, 0.913, 0.892 and 0.896, respectively. There were no significant differences between them. CONCLUSION: BBTs are often small solid tumors with sparse color Doppler signals, which contain calcifications with posterior acoustic shadowing. The most common pattern of MBT is a large multilocular-solid or solid mass with irregular tumor borders, and most were moderately or richly vascularized at color Doppler. These four models have excellent performance in distinguishing them.


Assuntos
Doenças dos Anexos , Tumor de Brenner , Neoplasias Ovarianas , Feminino , Humanos , Tumor de Brenner/diagnóstico por imagem , Tumor de Brenner/patologia , Estudos Retrospectivos , Neoplasias Ovarianas/patologia , Medição de Risco , Ultrassonografia , Antígeno Ca-125 , Doenças dos Anexos/patologia , Sensibilidade e Especificidade
5.
Am J Case Rep ; 24: e938680, 2023 Feb 13.
Artigo em Inglês | MEDLINE | ID: mdl-36775948

RESUMO

BACKGROUND Ovarian cancer is the leading cause of death in women with gynecological cancers. Ovarian Brenner tumor (BT) is an extremely rare type of epithelial ovarian cancer that accounts for about 1-3% of all ovarian cancers. Herein, we report a rare case of ruptured malignant ovarian Brenner tumor. CASE REPORT A 39-year-old P0A0 woman came to the Emergency Department (ED) with abdominal pain and tenderness. Perforated appendicitis was initially suspected and an emergency laparotomy was performed by the General Surgery Department. Then, a 25×20×15 cm grayish cystic mass originating from the right adnexa was found. We consulted intraoperatively with the Gynecology Oncology Department and decided to perform complete surgical staging. Histopathological examination confirmed the diagnosis of malignant Brenner tumor (MBT). The patient was then given adjuvant chemotherapy with a paclitaxel carboplatin regimen. In this case report, we present our case along with a review of the current literature regarding the diagnosis and therapy of malignant Brenner tumor. CONCLUSIONS Ovarian MBT is an extremely rare ovarian cancer. Diagnosing MBT can be challenging as there are no clinical, laboratory, or imaging features typical for it. Surgery is the mainstay treatment in MBT cases. The role of adjuvant chemotherapy in MBT is still being debated.


Assuntos
Tumor de Brenner , Neoplasias Ovarianas , Feminino , Humanos , Adulto , Tumor de Brenner/diagnóstico , Tumor de Brenner/cirurgia , Tumor de Brenner/patologia , Neoplasias Ovarianas/diagnóstico , Neoplasias Ovarianas/cirurgia , Neoplasias Ovarianas/patologia , Dor Abdominal/etiologia
6.
Med Sci (Basel) ; 11(1)2023 02 07.
Artigo em Inglês | MEDLINE | ID: mdl-36810485

RESUMO

Brenner tumors (BTs) are surface-epithelial stromal cell tumors that are categorized by the World Health Organization as benign, borderline, and malignant. Due to the rarity of BTs, the published literature on these tumors is comprised primarily of case reports and small retrospective studies. We performed a pathology database review spanning the last ten years at our institution revealing nine reported benign BTs. We collected the clinical and pathological data of patients associated with those BTs, describing the clinical presentation and imaging results, and assessing the possible risk factors associated with them. The average age at diagnosis was 58 years. BTs were discovered incidentally in 7/9 cases. The tumor was multifocal and bilateral in 1/9 cases and ranged in size from 0.2 cm to 7.5 cm. Associated Walthard rests were found in 6/9 cases and transitional metaplasia of surface ovarian and/or tubal epithelium was found in 4/9 cases. One patient had an associated mucinous cystadenoma in the ipsilateral ovary. Another patient had an associated mucinous cystadenoma in the contralateral ovary. In conclusion, we found that Walthard rests and transitional metaplasia are common findings in association with BTs. Additionally, pathologists and surgeons need to be aware of the association between mucinous cystadenomas and BTs.


Assuntos
Tumor de Brenner , Cistadenoma Mucinoso , Neoplasias Ovarianas , Feminino , Humanos , Pessoa de Meia-Idade , Cistadenoma Mucinoso/diagnóstico , Cistadenoma Mucinoso/patologia , Cistadenoma Mucinoso/cirurgia , Neoplasias Ovarianas/patologia , Estudos Retrospectivos , Tumor de Brenner/diagnóstico , Tumor de Brenner/metabolismo , Tumor de Brenner/patologia , Metaplasia
7.
Int J Gynecol Pathol ; 42(2): 176-181, 2023 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-35283447

RESUMO

While angiosarcoma metastatic to the ovary is rare, metastatic angiosarcoma to an ovarian tumor has never been reported in the literature, so far. We report a case of a 61-yr-old postmenopausal woman with history of breast cancer, presenting with metastatic angiosarcoma to an ovarian Brenner tumor. Initially at the frozen section examination, on limited sampling, and without knowledge of the patient's history, a diagnosis of at least proliferating Brenner tumor was rendered. Upon review of permanent sections, an intermixed angiosarcoma component was identified within Brenner tumor. Tumor to ovarian tumor metastasis is a rare phenomenon, with only 18 cases reported in the last 50 yr. It poses diagnostic challenges during sampling and histopathologic interpretation. Detailed clinical history, careful gross examination and sampling are important to recognize the separate tumor components.


Assuntos
Tumor de Brenner , Hemangiossarcoma , Tumor de Krukenberg , Segunda Neoplasia Primária , Neoplasias Ovarianas , Feminino , Humanos , Tumor de Brenner/diagnóstico , Hemangiossarcoma/diagnóstico , Neoplasias Ovarianas/patologia
8.
Ir J Med Sci ; 192(5): 2071-2075, 2023 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-36409423

RESUMO

Ovarian Brenner tumor with abnormally increased serum carbohydrate antigen 19-9 (CA19-9) level is extremely rare. A 70-year-old woman with abnormally elevated serum CA199 (1289 U/ml) found in routine physical examination. Pelvic CT and MRI scan revealed a large mass with large patches of calcification in the right adnexal area, and the patient achieved total hysterectomy and bilateral adnexectomy. Grossly, the right ovary had a solid enlargement of about 7.0 cm × 6.0 cm × 5.0 cm with irregular nodules and smooth surface and the cut surface of the mass showed that the tumor is cystic and solid. Microscopically, the tumor showed a background of fibrous tissue hyperplasia with nested and adenoid cell clusters with uniform cell size and clear boundaries. The cells were translucent with eosinophilic cytoplasm and calcification. Immunohistochemical staining showed CK7, CA125, and P63 presented diffusely strongly positive staining, while negativity for CK20, GATA3, AR, P53, and CgA. Ki-67 showed weak positive staining, about 1%. The serum CA199 level decreased significantly on the 5th day after surgery. Postoperative pathology and immunohistochemistry confirmed borderline Brenner tumor. This is the first to report a case of borderline Brenner tumor with an abnormally high serum level of CA199 before surgery. In clinical practice, the possibility of ovarian Brenner tumor should be considered when abnormal elevation of serum CA199 level cannot be reasonably explained.


Assuntos
Tumor de Brenner , Neoplasias Ovarianas , Feminino , Humanos , Idoso , Tumor de Brenner/diagnóstico , Tumor de Brenner/cirurgia , Tumor de Brenner/patologia , Neoplasias Ovarianas/cirurgia , Biomarcadores Tumorais , Carboidratos
9.
BMJ Case Rep ; 15(12)2022 Dec 21.
Artigo em Inglês | MEDLINE | ID: mdl-36543369

RESUMO

Endometrial hyperplasia (EH) is a precursor of endometrial cancer. It arises in an environment of unopposed oestrogen. Treatment is based on a combination of weight management, diet and exercise, and the use of progestogens either via a levonogestrel-intrauterine system (LNG-IUS) or orally. The LNG-IUS is the first-line recommendation for EH without atypia. Recurrences are rare, and any recurrences despite prolonged treatment and control of risk factors necessitate a thorough consideration of other oestrogenic sources. This case report presents a rare case of a coexisting ovarian Brenner tumour and ovarian stromal hyperplasia in a menopausal patient in her 50s with recurrent EH despite earlier regression. The above histology may have provided the additional oestrogenic influence. This patient subsequently underwent a definitive hysterectomy and bilateral salpingo-oophorectomy (BSO). It is important to maintain a high index of suspicion for potential oestrogenic influences in cases of refractory EH that are not identifiable on imaging. BSO should be considered at the time of hysterectomy in such cases of unidentified oestrogenic foci.


Assuntos
Tumor de Brenner , Hiperplasia Endometrial , Dispositivos Intrauterinos Medicados , Neoplasias Ovarianas , Feminino , Humanos , Levanogestrel/efeitos adversos , Hiperplasia Endometrial/induzido quimicamente , Hiperplasia Endometrial/complicações , Hiperplasia Endometrial/patologia , Hiperplasia/induzido quimicamente , Dispositivos Intrauterinos Medicados/efeitos adversos , Neoplasias Ovarianas/complicações
10.
Psychoanal Q ; 91(3): 557-565, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36346760
11.
Psychoanal Q ; 91(3): 547-555, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36346765
13.
BMJ Case Rep ; 15(8)2022 Aug 25.
Artigo em Inglês | MEDLINE | ID: mdl-36007970

RESUMO

Brenner's tumour of the ovary is a rare diagnosis that is usually incidental in either clinical finding or laparotomy. Pathologically, it can be classified as being an uncommon surface epithelial tumour. Originally known as a transitional cell tumour due to its histological similarity to the urothelium, Brenner is usually an unilateral and benign tumour. The site of incidence is predominantly the ovary and can very rarely occur in other locations including the testis. The following is a case of Brenner's tumour of the ovary in a postmenopausal woman after surgical treatment, the features of which will be discussed briefly.


Assuntos
Tumor de Brenner , Neoplasias Epiteliais e Glandulares , Neoplasias Ovarianas , Tumor de Brenner/diagnóstico , Tumor de Brenner/patologia , Tumor de Brenner/cirurgia , Feminino , Humanos , Neoplasias Ovarianas/diagnóstico , Neoplasias Ovarianas/patologia , Neoplasias Ovarianas/cirurgia , Pelve/patologia
15.
Br J Radiol ; 95(1130): 20210687, 2022 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-34928171

RESUMO

Brenner tumors are rare ovarian neoplasms composed of ovarian transition cells surrounded by dense fibrous tissue. Most of them are small tumors (<2 cm), detected incidentally in asymptomatic women. Its predominantly fibrous content results in relatively low signal on T2 weighted images, establishing differential diagnosis with ovarian fibroma and thecoma. Their imaging features are very similar, the differentiation is based on secondary characteristics, such as signs or symptoms of estrogen excess and the presence of a second ovarian neoplasm, which has been reported in up to 30% of patients with Brenner tumor. Although originally thought to be universally benign, there have been scattered reports in the past decades of borderline and malignant forms of Brenner tumors.


Assuntos
Tumor de Brenner/diagnóstico por imagem , Neoplasias Ovarianas/diagnóstico por imagem , Doenças Raras/diagnóstico por imagem , Tumor de Brenner/patologia , Cistoadenofibroma/diagnóstico por imagem , Diagnóstico Diferencial , Feminino , Fibroma/diagnóstico por imagem , Fibroma/patologia , Humanos , Leiomioma/diagnóstico por imagem , Imageamento por Ressonância Magnética , Neoplasias Ovarianas/patologia , Doenças Raras/patologia , Tumor da Célula Tecal/diagnóstico por imagem , Tumor da Célula Tecal/patologia , Tomografia Computadorizada por Raios X , Ultrassonografia
16.
Int J Gynecol Pathol ; 41(3): 276-284, 2022 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-34015796

RESUMO

Brenner tumors are uncommon ovarian neoplasms, most of which are benign, although borderline and malignant variants occur. We report 2 unusual ovarian neoplasms composed of an admixture of typical benign Brenner tumor and a low-grade epithelial neoplasm which we designate as low-grade basaloid carcinoma. The latter component morphologically and immunohistochemically resembled "salivary gland-type/myoepithelial" neoplasms with variable positive staining with cytokeratins, p63, S100, and CD117. One tumor exhibited aggressive behavior with local recurrence and distant metastasis. This neoplasm exhibited focal "high-grade" transformation with diffuse mutation-type p53 staining, in contrast to the wild-type immunoreactivity in the low-grade component. As far as we are aware, such neoplasms have not previously been reported in the literature and this represents a newly described morphologic variant of malignant Brenner tumor.


Assuntos
Tumor de Brenner , Carcinoma de Células de Transição , Neoplasias Ovarianas , Neoplasias das Glândulas Salivares , Tumor de Brenner/diagnóstico , Tumor de Brenner/patologia , Carcinoma de Células de Transição/patologia , Feminino , Humanos , Neoplasias Ovarianas/patologia
17.
Ceska Gynekol ; 86(4): 250-257, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34493050

RESUMO

OBJECTIVE: Description of the case of recurrence of a rare malignant Brenner ovarian tumour. METHODS: Author observation and literature resources. RESULTS: Occurrence of a rare malignant Brenners tumor in a 66-year-old patient. After radical surgery (abdominal hysterectomy with bilateral adnexectomy, pelvic and paraaortic lymphadenectomy, omentectomy and appendectomy) and after adjuvant chemotherapy, recurrence of the disease was observed after 30 months. CONCLUSIONS: The case report describes rare occurrence of a malignant Brenner tumour and its relapse.


Assuntos
Tumor de Brenner , Neoplasias Ovarianas , Idoso , Tumor de Brenner/cirurgia , Feminino , Humanos , Histerectomia , Recidiva Local de Neoplasia/cirurgia , Neoplasias Ovarianas/cirurgia
18.
Hum Pathol ; 117: 42-50, 2021 11.
Artigo em Inglês | MEDLINE | ID: mdl-34391746

RESUMO

Malignant Brenner tumor (MBT) is diagnosed in the setting of invasive high-grade carcinoma with urothelial-like morphology and the presence of an adjacent benign Brenner tumor (BBT) or borderline Brenner tumor (BLBT). MDM2 amplification was recently detected by next-generation sequencing on a small number of MBTs, potentially significant for future targeted therapy. Experience is limited, however, and evaluation of widely available MDM2 immunohistochemistry (IHC) has not been performed to determine clinical utility. After confirming all diagnoses morphologically and immunohistochemically, we performed MDM2 IHC on 4 MBTs, 3 BLBTs, 26 BBTs, 142 high-grade serous carcinomas (HGSC), 6 ovarian endometrioid carcinomas (OEC) with urothelial-like morphology, and 49 high-grade urothelial carcinomas (HGUC). MDM2 IHC was considered positive with diffuse (>25%) nuclear reactivity; in cases of patchy staining (10-25% nuclear reactivity), MDM2 was considered equivocal. Positive staining in <10% of cells was considered negative. In cases with positive or equivocal staining, MDM2 amplification was evaluated by fluorescence in-situ hybridization (FISH). Three MBTs (75%) showed diffuse nuclear reactivity for MDM2 by IHC, a finding corroborated by amplification of MDM2 in all three cases. One MBT and 2 BLBTs showed equivocal MDM2 IHC, but all three were negative for MDM2 amplification. The final BLBT, as well as all BBTs, HGSC, OEC, and HGUC, were negative for MDM2. In conclusion, our limited cohort confirms MDM2 amplification in MBT and suggests that MDM2 IHC may have an influence in rare diagnostically challenging cases.


Assuntos
Biomarcadores Tumorais/análise , Tumor de Brenner/patologia , Carcinoma de Células de Transição/diagnóstico , Neoplasias Ovarianas/patologia , Proteínas Proto-Oncogênicas c-mdm2/análise , Adulto , Idoso , Idoso de 80 Anos ou mais , Tumor de Brenner/diagnóstico , Carcinoma de Células de Transição/genética , Diagnóstico Diferencial , Progressão da Doença , Feminino , Amplificação de Genes , Humanos , Imuno-Histoquímica , Pessoa de Meia-Idade , Neoplasias Ovarianas/diagnóstico , Proteínas Proto-Oncogênicas c-mdm2/genética , Proteínas Proto-Oncogênicas c-mdm2/metabolismo
19.
Clin Radiol ; 76(8): 593-598, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-33933275

RESUMO

AIM: To evaluate the computed tomography (CT) and magnetic resonance imaging (MRI) features of benign Brenner tumours (BBT) of the ovary. MATERIAL AND METHODS: This was a retrospective two-centre study comprising 35 female patients with a definitive diagnosis of BBT at histology in whom CT and/or MRI examinations had been performed. Two experienced radiologists reviewed the CT and MRI features of 39 ovarian BBT retrospectively with consensus reading. The morphological appearance and size of each tumour were recorded. The presence or absence of calcifications within the solid portion was noted at CT. The reviewed characteristics at MRI included qualitative assessment of the signal intensity of the solid portion on diffusion sequence and contrast enhancement, compared to that of the myometrium. RESULTS: CT and MRI images were available for 27 and 28 lesions, respectively. Sixteen patients had both CT and MRI examinations. BBT were unilateral in 89% of patients, and 49% of lesions were solid and 51% were mixed. Calcifications were depicted at CT in 70.4% of lesions. When present, the cystic portion was multilocular in 85% of cases and corresponded to a mucinous lesion in 74% of cases. Enhancement of the solid portion at MRI was inferior or equal to that of the myometrium in 89% of cases and signal on high b-values diffusion images was deemed low or moderate in 93% of cases. CONCLUSION: The combined CT and MRI findings of a unilateral fibrous ovarian mass containing punctate calcifications often associated with a multilocular cyst suggest the diagnosis of ovarian BBT.


Assuntos
Tumor de Brenner/diagnóstico por imagem , Imageamento por Ressonância Magnética/métodos , Neoplasias Ovarianas/diagnóstico por imagem , Tomografia Computadorizada por Raios X/métodos , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Pessoa de Meia-Idade , Ovário/diagnóstico por imagem , Estudos Retrospectivos
20.
Hum Pathol ; 113: 84-91, 2021 07.
Artigo em Inglês | MEDLINE | ID: mdl-33812844

RESUMO

The association of Brenner tumor (BT) with rete ovarii (RO) has been rarely alluded to in the literature. Both entities have debatable histogenesis. In this study of six cases of BT associated with RO, we describe the morphologic features and performed immunohistochemical staining for markers of Mullerian, Wolffian, mesothelial, and sex cord stromal derivation to explore the relationship between these entities. Histologically, all BTs were benign, microscopic, and incidental. RO was prominent and hyperplastic with gradual or abrupt transition to BT. In addition, focal areas of rete entrapped between BT nests were seen. All BTs were positive for GATA-3 and negative for PAX-8. Conversely, the RO in all cases was negative for GATA-3 and positive for PAX-8. WT-1 was positive in both entities. Sex cord stromal and mesothelial markers (other than WT-1) were negative in BT and RO. Although morphologically, BTs seem to arise from RO in these cases, they have a distinct immunophenotype. It is possible that at least some BTs arise from metaplastic changes in RO epithelium.


Assuntos
Biomarcadores Tumorais/análise , Tumor de Brenner/patologia , Linhagem da Célula , Imuno-Histoquímica , Neoplasias Ovarianas/patologia , Ovário/patologia , Adulto , Idoso , Biópsia , Tumor de Brenner/química , Tumor de Brenner/cirurgia , Feminino , Humanos , Metaplasia , Pessoa de Meia-Idade , Neoplasias Ovarianas/química , Neoplasias Ovarianas/cirurgia , Ovário/química , Ovário/cirurgia , Valor Preditivo dos Testes , Estudos Retrospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...